Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.
Aria VaishnaviJoseph JuanMaebh JacobChristopher M StehnEric E GardnerMichael T ScherzerSophia SchumanJ Edward Van VeenBrandon MurphyChristopher S HackettAdam J DupuyStephen A ChmuraLouise van der WeydenJustin Y NewbergAnnie LiuKaren M MannAlistair G RustWilliam A WeissConan G KinseyDavid J AdamsAllie H GrossmannMichael B MannMartin McMahonPublished in: Cancer research (2022)
Loss of RBMS3 cooperates with BRAFV600E to induce lung tumorigenesis, providing a deeper understanding of the molecular mechanisms underlying mutant BRAF-driven lung cancer and potential strategies to more effectively target this disease.